Cargando…

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen

Background and objectives Tuberculosis (TB) is an airborne contagious illness caused by Mycobacterium tuberculosis. Ineffective anti-TB medication prolongs and exasperates illness, promotes disease spread, increases the probability of developing resistance to treatment, and increases death rate. Be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paikray, Elisha, Das, Priti, Pattnaik, Manoranjan, Mishra, Vedvyas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Pulmonology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701089/ https://www.ncbi.nlm.nih.gov/pubmed/36447692 http://dx.doi.org/10.7759/cureus.30764

Ejemplares similares

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Pulmonary Tuberculosis Versus Recurrent Chemotherapy-Induced Pneumonitis: A Clinical Dilemma
por: Ahmed, Gulrayz, et al.
Publicado: (2017)

Diagnostic Accuracy of Xpert MTB/RIF in Sputum Smear-Negative Pulmonary Tuberculosis
por: Rasheed, Waqas, et al.
Publicado: (2019)

Correlations Between Inflammatory Biomarkers in Tuberculosis-Associated Obstructive Pulmonary Disease Patients With Anxiety and Depression
por: Katare, Srikanth, et al.
Publicado: (2022)

Anemia as a Significant Predictor of Adverse Outcomes in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Analysis of National (Nationwide) Inpatient Sample Database
por: Sonani, Hardik, et al.
Publicado: (2023)

Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
por: Giri, Om P, et al.
Publicado: (2022)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

E-cigarette and Vaping-Induced Lung Injury (EVALI) Long Taken for Miliary Tuberculosis: A Rare Cause of Interstitial Lung Disease
por: Rachid, Chaynez, et al.
Publicado: (2023)

Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid
por: Nieto Ramirez, Luisa Maria, et al.
Publicado: (2020)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
por: Rodriguez, Carly A., et al.
Publicado: (2023)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in Bangladesh: A Systematic Review
por: Sutradhar, Ipsita, et al.
Publicado: (2019)

Erratum: Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid: A Prospective Multicountry Study
Publicado: (2021)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jjkngb2tsi5luft5gvies721h4